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The complexity and rapid growth of genetic data demand investment in information technology to sup-
port effective use of this information. Creating infrastructure to communicate genetic information to
healthcare providers and enable them to manage that data can positively affect a patient’s care in many
ways. However, genetic data are complex and present many challenges. We report on the usability of a
novel application designed to assist providers in receiving and managing a patient’s genetic proﬁle,
including ongoing updated interpretations of the genetic variants in those patients. Because these inter-
pretations are constantly evolving, managing them represents a challenge. We conducted usability tests
with potential users of this application and reported ﬁndings to the application development team, many
of which were addressed in subsequent versions. Clinicians were excited about the value this tool pro-
vides in pushing out variant updates to providers and overall gave the application high usability ratings,
but had some difﬁculty interpreting elements of the interface. Many issues identiﬁed required relatively
little development effort to ﬁx suggesting that consistently incorporating this type of analysis in the
development process can be highly beneﬁcial. For genetic decision support applications, our ﬁndings sug-
gest the importance of designing a system that can deliver the most current knowledge and highlight the
signiﬁcance of new genetic information for clinical care. Our results demonstrate that using a develop-
ment and design process that is user focused helped optimize the value of this application for personal-
ized medicine.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Personalized medicine—the incorporation of an individual’s
genetic makeup into the management of their care—has the poten-
tial to play a major role in the future of healthcare. While there are
few successful examples of the routine use of genetic information
in guiding patient care to date, the prospective beneﬁts are great.
As evidenced-based use of genetic data becomes more common
for a variety of purposes, there is a growing need for information
technology (IT) to support the management of the rapidly expand-
ing knowledge [1,2].
One speciﬁc challenge that genetic counselors, geneticists, and
clinicians regularly face today is how to track the changing state
of knowledge about genetic variants, including those of unknown
signiﬁcance. Our understanding of the clinical implications ofll rights reserved.
eet, 2nd Floor, Wellesley, MAvariants evolves as new scientiﬁc evidence becomes available, so
obtaining new information on previously reported variants is
important for clinical care [3].
For example, with hypertrophic cardiomyopathy, new knowl-
edge about variants may critically inﬂuence the treatment of pa-
tients and their families and, in some circumstances, help prevent
sudden cardiac death [4]. However, typical processes in place for
learning about and managing variant updates (changes in knowl-
edge relating to the clinical signiﬁcance of variants) have many
challenges. Currently, it is not standard practice for labs to contin-
ually re-evaluate variants and contact treating clinicians [5]. How-
ever, for laboratories that do, there are a large number of variants to
track as scientiﬁc knowledge changes over time, and the cost to the
lab to amend old reports with every variant update is high, partic-
ularly since this is not currently reimbursed by payers. In addition,
while treating clinicians are ultimately responsible for managing
the care of patients, in most cases they do not have the capacity, gi-
ven their case load, to remain up-to-date on all variants affecting
their patients [6,7]. Laboratories may be in the best position to
monitor the current state of knowledge on the variants they have
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infrastructure and applications to support clinicians and laborato-
ries in this process are necessary. Designing systems that satisfy
the needs of the users and are ﬂexible enough to handle the contin-
ued evolution of this complex and emerging area is an important
step in realizing the beneﬁts of personalized medicine.
Involving treating clinicians early in the design process and
generating requirements based on user research can reduce devel-
opment and support costs, increase user satisfaction, and ensure
the user’s long term commitment to the application [9,10]. In addi-
tion, using principles of human factors and usability to evaluate
systems can help prevent errors, delays and frustrations that, left
unaddressed, may result in underuse or even abandonment of sys-
tems [11–14]. Designing interfaces that support the user’s natural
process for decision making, problem solving and information pro-
cessing will allow the user to conduct their work with a minimum
amount of unnecessary cognitive effort [15].
While user-centered design has rather rapidly diffused into
many industries in the last decade, challenges speciﬁc to health-
care applications have resulted in developers and vendors of these
applications being slower to implement this philosophy [15–17]. A
number of reports have been published recently by the Agency
for Healthcare Research and Quality and National Institute of
Standards and Technology in hopes of creating guidelines around
incorporating human factors and usability in the design of health
IT [16,18]. More limited access to users and the complexity and
sensitivity of patient data are just some of the challenges faced
by those developing such applications [19,20].
The volume and continual evolution of variant knowledge re-
quires a system and interface that is designed to support complex
decision-making and knowledge that changes frequently. For
example, in the last 6 years, the Laboratory for Molecular Medi-
cine (LMM) at the Partners HealthCare Center for Personalized
Genetic Medicine (PCPGM) has made approximately 214 category
changes to previously reported variants associated with just one
condition, hypertrophic cardiomyopathy, impacting nearly 756
patients [21,22]. In order to effectively manage the growing num-
ber of genetic test results and changing knowledge of variants, cli-
nicians will need interfaces that will allow them to efﬁciently
review genetic test results, provide the most up-to-date informa-
tion to their patients with conﬁdence and easily identify patients
and families that may require changes to their treatment and
testing plans.
Understanding how clinicians use these tools and evaluating
them early is critical to successful development and use of these
applications. As part of a broader study evaluating the usability
and utility of an application for tracking variants and the value of
more timely genetic variant information, we conducted a usability
assessment of the ﬁrst version of a novel application prior to its
implementation in a healthcare clinic. Results of these analyses
were used to further enhance the application prior to additional
development and broader distribution.
2. Methods
2.1. GeneInsight Clinic application description
The Partners HealthCare Center for Personalized Genetic
Medicine developed the GeneInsight suite of applications to
provide infrastructure around managing genetic data [23]. The
GeneInsight Lab component provides IT infrastructure for the lab-
oratory, assisting in genetic knowledge management and report
generation. To support the management and communication of ge-
netic test results and variant updates to clinicians, a new innova-
tive web-based application was developed. GeneInsight Clinic(GIC), as part of the GeneInsight suite, was created with the goal
of providing healthcare providers the ability to fully manage their
patient genetic proﬁles [6]. GeneInsight delivers structured elec-
tronic genetic reports and generates physician alerts when new
knowledge is identiﬁed on variants in their patients. One impor-
tant element in accomplishing the goals of this new tool and pro-
cess is to ensure that the design of GIC satisﬁes the needs of the
users and is ﬂexible to handle continued evolution of this emerging
area.
GIC utilizes a web-based interface that allows the clinician to
access a complete electronic summary and history of a patient’s ge-
netic proﬁle. In addition to the application, a new process was
developed to deliver patient-speciﬁc alerts notifying clinicians
about the availability of genetic reports in the system or updates
to their patients’ variants. The clinicians receive these alerts
through email with a link to the information in GIC. Currently, each
GIC contains information on all patients within the clinic receiving
genetic testing through the LMM. Email notiﬁcations of ﬁnal re-
ports and variant updates regarding their patients are sent to all
providers within the clinic. To assist in determining what updates
should be emailed to the clinician and at what frequency, variant
updates are classiﬁed based on the signiﬁcance of the change in
knowledge into one of three alert categories: high, medium, or
low (see Appendix for types of variant changes and their alert lev-
els). The lab updates the category in the GeneInsight Lab compo-
nent of the system. The approval of the change in variant
category triggers the logic that generates the update and sends
the email to the appropriate clinic. High variant change alerts are
emailed to the clinician as soon as the updates are approved by
the lab, and medium and low alerts are emailed to the clinician
in a weekly summary email, along with a list of any unreviewed
high alerts or new report alerts.
The GIC interface includes four main pages. The Search page al-
lows clinicians to conduct: (1) a patient search, or (2) a variant
search resulting in a list of patients in that clinic presenting with
that variant. Once a single patient is selected, the Tests page
(Fig. 1) has detailed information on the patient’s genetic test re-
sults including reported variants and any updated variant informa-
tion. The Case Report Details page includes some structured
elements of the patient’s report as well as a portable document
format (.pdf) copy of the full ﬁnal report issued by the lab. The
Individual Reported Variant Interpretation History page (Fig. 2) in-
cludes more speciﬁc information on each variant for the patient
including supporting evidence for any category changes to the var-
iant, as well as the current state of knowledge on the variant. Users
have the ability to mark that reports have been reviewed by click-
ing a ‘‘mark reviewed’’ button on the Tests page. Similarly, users
can mark that variant updates have been reviewed by using a
‘‘mark reviewed’’ button on the Individual Reported Variant
Interpretation History page [21].
Some of the initial designs for the GIC interface were evaluated
by the usability specialist (PN) prior to participant recruitment and
usability testing. The usability specialist on the research team con-
ducted an expert review of some of the early designs and provided
a short report of recommendations to the development team based
on standard usability heuristics [24]. In addition, the usability spe-
cialist provided informal reviews of subsequent prototypes. The
design evaluated during the usability tests was the ﬁrst version
tested with users.
2.2. Participants and recruitment
The evaluation was approved by the Partners HealthCare
System Human Research Committee and was conducted at two
academic medical centers.
Fig. 1. GeneInsight Clinic patient reports view (Tests page) (Version 3.8) – this page displays a summary of genetic test report results and variant knowledge updates on an
individual patient. Users can view the report and obtain speciﬁc information about the variants listed by clicking on the variant links. Users can also mark a report reviewed
by using the button provided (not shown).
Fig. 2. GeneInsight Clinic Individual Reported Variant Interpretation History page (Version 3.8) – users navigate to this page by clicking on the variant name on the patient
reports view for an individual patient. Information regarding the individual variant’s history including alerts on variant knowledge changes and current interpretation is
provided on this page. The user can mark alerts reviewed using the button provided.
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cians, genetic counselors, nurse practitioners and nurses at two
locations where GIC was being implemented. Both clinics order a
large number of genetic cardiomyopathy tests from the Laboratory
for Molecular Medicine. Participants had the opportunity to opt out
of the broader study and subsequently, if they did not choose to opt
out, an email was sent to request participation in the usability study
component. Seven clinicians froma clinic in the PartnersHealthCare
System and two clinicians from an academic medical center in a
Midwestern state consented to participate in the ﬁrst round of
usability testing. No remuneration was provided for participation.2.3. Task scenario development
Before the testing sessions, usability testing scenarios were
developed from screen shots and use cases with the assistance of
subject-matter experts (MV, HR). The scenarios were identical for
all participants, regardless of their clinical role. The scenarios were
reviewed by all research teammembers to ensure that the content,
format, and presentation were representative of real expected use
and addressed the major functional components of the application.
Most of the common and critical tasks were placed at the begin-
ning of the testing session.
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tients that were appropriate for each clinical scenario. The test pa-
tients and clinical scenarios were reviewed by members of the
tool’s development team and subject matter expert, and the usabil-
ity test was piloted by a genetic counselor on the research team
(SB). The pilot participant was not involved in the development
of the tasks and did not see the tasks before doing the usability
test. After the test, the pilot participant offered feedback on the
usability testing process, as well as the content and wording of task
scenarios. As a result of the feedback, some task scenarios and test
patients’ content were revised.
2.4. Testing environment and equipment
All usability tests were conducted on-site in a conference room
at the participants’ ofﬁce at both clinic sites. Two members of the
research team were present, the usability specialist (PN) served as
the moderator and an observer (SP) transcribed the session and
annotated task markers and other metrics using the Morae Obser-
ver software [25]. The participant’s interaction with the interface
was observed and moderated by the usability specialist who sat
next to and slightly behind the participant during the testing ses-
sion. Morae Recorder software was running on the participant’s
laptop to capture keystrokes, and audio and video of the session.
The moderator had a paper version of the test script to capture
additional observations and notes during the testing session.
Some of the testing scenarios involved using one of the GIC
email messages: Report Alert, Variant Update Alert, and Summary
Alert. A study speciﬁc Microsoft Outlook mailbox was used to mi-
mic the participants’ email. Folders were set up in the mailbox for
each study participant, and each folder contained the set of three
emails required for the tasks. Each participant was given a user-
name and password to log into the application.
2.5. Usability test procedure
A usability test plan was developed and reviewed by the re-
search team prior to testing. The test plan included details on the
testing procedure, tasks, usability metrics, usability goals, and
appendices of the scenarios, pre-test instructions, usability ques-
tionnaire, and post-test interview questions.
At each testing session, the moderator described the usability
test procedure to the participant using scripted pre-test instruc-
tions to ensure all participants received the same introduction.
The moderator described the ‘‘think aloud’’ process, asking the par-
ticipants to share their thought process and expectations while
completing the tasks [26,27]. An example of ‘‘think aloud’’ was also
demonstrated to participants. The participant was told that the
purpose of the study was to evaluate the GIC and that the usability
testing session was being recorded.
After the moderator discussed the pre-test instructions with the
participant, they were introduced to the tool and began the task
scenarios. They were asked to read each task aloud and inform
the moderator when they completed the task. At the end of each
task, the moderator asked the participant to grade the task
(A? F) based on how easy/difﬁcult it was to complete. Once the
participant completed all the tasks, they were asked to complete
a written questionnaire, the System Usability Scale (SUS) [28], to
assess their overall feelings about the GIC. The participants ranked
their agreement with 10 statements based on a ﬁve point Likert-
type scale to assess overall perceived usability. The moderator then
administered a six question verbal post-test interview regarding
their experience with the tool, recommendations for enhance-
ments and expected value of the tool in their practice. For the
remainder of the session, the moderator solicited additional feed-
back on the four main screens of the GIC. Participants were askedto suggest the intended function or meaning of certain interface
elements (i.e., icons, links and labels) and interpret speciﬁc content
on these screens.2.6. Usability metrics and data collection
In addition to the observations and comments captured during
the testing session, usability measurements were recorded during
the test or in the post-test analysis of the session video. Usability
metrics are measurements collected to determine to what extent
the usability goals have been met and to compare those measure-
ments to those gathered from subsequent tests to assess whether
design changes have made a difference. Task completion success
rates, time-on-task, error rates, and assists by the moderator were
collected for each participant during the testing session and coded
during the post-test analysis.
Each scenario requested that the participant obtain speciﬁc data
or complete speciﬁc actions that would be used in the course of the
task. We recorded task success or failure based on the intended
outcome as indicated in the ﬁnal test plan.
Participants who were having trouble completing the tasks
were given assists at the moderator’s discretion. An assist is de-
ﬁned as active direction by the moderator to the participant in or-
der to help them achieve the task goal. Assists were only given
when the participant was visibly frustrated or did something that
would prevent completion of subsequent tasks. We captured the
number of assists and included them as a metric in the analysis.
We measured the time for each task by noting the start and end
times for each task (beginning when the participant ﬁnished read-
ing the task scenario and ending when the participant either com-
pleted the task or indicated to the moderator that they believed
they completed the task). When a participant required an assist,
the time on task included the assist time. We also captured errors
that occurred during the completion of the tasks. Errors can in-
clude those that would not have an impact on the ﬁnal output of
the task but would result in the task being completed less efﬁ-
ciently. Other errors, such as obtaining incorrect information, could
result in task failure.2.7. Data analysis and reporting
Each usability test session was recorded and analyzed using
Morae software. The moderator and the observer reviewed each
recording together to log the time on task, errors, assists and task
completion for each participant. In addition, the moderator and
observer marked speciﬁc quotes and usability issues that the par-
ticipants encountered during the test. During multiple reviews of
the Morae recordings and transcripts of the sessions, the usability
specialist identiﬁed usability issues based on observations of the
participants during the task and their think-aloud comments. The
transcripts of the usability tests were organized by task and partic-
ipant, and quotes were identiﬁed that illustrated a user expecta-
tion, frustration or misinterpretation of content or functionality.
The frequency of the issue, identiﬁed by the number of participants
experiencing the problem, was captured. In addition, the usability
heuristic related to each problem was identiﬁed. Finally, the issue
was categorized based on how much of the system was affected.
For example, a global issue affects multiple pages of the site and
a local issue is speciﬁc to a particular interface element [24,27].
The usability test report generated for the GIC development
team included tables summarizing the usability metrics as well as
a summary of the usability ﬁndings, organized by their scope and
frequency with direct quotes from participants to support the anal-
ysis. In addition, a highlight video was generated with the consent
of participants that included clips from the participants’ usability
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ﬁndings.
2.8. Dissemination of ﬁndings
The report was provided to all members of the Research team as
well as members of the Quality Assurance and Development teams.
The highlight video and major ﬁndings were presented and dis-
cussed at a meeting with the entire group.
3. Results
3.1. Participant characteristics
The seven participants who participated from the two sites in-
cluded two genetic counselors, one nurse practitioner, one nurse
and three physicians (Table 1). Five out of the seven participants
were introduced to the tool months previously through a demo
presentation. None of the participants received formal training or
had the opportunity to review the user guide before participating
in a usability test.
3.2. Usability ﬁndings
Users were able to perform critical activities such as viewing a
patient’s genetic test results and high level variant updates and
searching patients on multiple dimensions. Participants rarely felt
frustrated by the system although they did verbalize confusion or
uncertainty during some of the tasks. Almost all observed usability
issues fell under the following categories: icon inconsistencies,
labeling and language issues, and placement and organization.
Inconsistencies in the behavior and application of some icons
with external conventions and among screens of the applicationTable 1
Participants.
Clinic Role GeneInsigh
Site 1 Physician Demo
Site 1 Genetic Counselor Demo
Site 2 Physician Early demo
Site 2 Physician Early demo
Site 2 Research Nurse Coordinator None
Site 2 Nurse Practitioner None
Site 2 Genetic Counselor Early demo
Table 2
Summary of usability test results by task.
Task 1 – GIC Report Alert – locate patient with new report CRITICAL TASK
Task 2 – View Test Report and ‘Mark Reviewed’
Task 3 – GIC Variant Alert – locate patient(s) with variant update CRITICAL TASK
Task 4 – Locate unreviewed alert and change in variant interpretation CRITICAL TASK
Task 5 – Locate overall report interpretation
Task 6 – Locate number of reports and families with variant tested at lab
Task 7 – Locate evidence for variant update
Task 8 – Mark variant reviewed
Task 9 – Locate all of a patient’s variants. Locate reviewed variants info.
Task 10 – Locate variant history for reviewed variant
Task 11 – Conduct patient search by variant
Task 12 – Conduct a search for patients with unreviewed information
Task 13 – Locate alert on an incidental variant LOW PRIORITY TASK
Task 14 – Review GIC Alert Summary Email
a These results are calculated on six participants rather than 7 because the moderator
the capture of task time.led participants to misunderstand the process or status of the data
presented.
One participant expressed confusion about the meaning of
the icons, ‘‘I’m not sure the red thing – high level alert? The
green – lesser level? The ones without anything are insigniﬁcant
variant changes?’’ Other issues included organization of the sum-
mary email and labels on the review buttons and for the reported
probands and families counts that did not clearly indicate to some
users what they were for or what was being communicated. One
participant commented on the summary email, ‘‘There are so many
highs. . . I’m trying to see what is urgent. . .they are all saying high
alert and they are all high. I can’t sit and open each one. . ..’’ When
asked about the reported probands and families counts, one partic-
ipant incorrectly deﬁned the counts, stating ‘‘I would think that
would be a combo of reported in the lab and published....would
not include other labs, just published data and the LMM lab.’’
Enhancements were incorporated into the current version of the
software based on these usability ﬁndings. Participants were over-
all positive in their response to the interview questions. All partic-
ipants said that they would recommend the tool to colleagues and
that the tool would have a positive impact on their practice. One
participant shared their thoughts on the tool, ‘‘It’s nice to have
updated access to the variant interpretation because it is important
for patient management. . . it was really easy to use and
self-explanatory’’.3.3. Usability questionnaire
Overall scores from the post-test usability questionnaire
(System Usability Scale) indicate an above average perceived ease
of use. The overall average usability score was 89 out of 100 possi-
ble points across all participants. A score above an 80 places the
application in the top 10% of scores [28–30].t Clinic exposure prior to usability test Internet use
Daily
Daily
Daily
, meeting presentation Daily
Daily
Daily
, meeting presentation Daily
Task summary
Completion rate (n = 7) (%) Average grade (n = 7) Error-free rate (n = 7) (%)
100 A 100
100 A 100
100 A 100
85.7 A/A 71.4
100 A 71.4
14.3 B+a 14.3
100 A 100
57.1 Aa 57.1
57.1 B+ 42.9
85.7 B+/B 57.1
85.7 B 71.4
85.7 B+/B 85.7
14.3 A/A 14.3
100 B 100
failed to solicit a grade from the participant or the participant’s workﬂow prevented
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Measurements captured during the usability tests show base-
line results for the ﬁrst version of the GIC and will be used for com-
parison with usability test results of subsequent revised versions.
Geometric mean of time on task ranged from 8.17 s to 141.95 s.
Additional measurements are summarized in Table 2.
Error-free rate and completion rate ranged from 14.3% to 100%.
Six out of the 14 tasks (Tasks 1, 2, 3, 7 and 14) had a 100% comple-
tion and error-free rate. All participants were able to complete the
critical tasks of viewing a new patient report and a high level var-
iant update efﬁciently and without error. Locating the laboratory’s
data on the number of reports and families (Task 6) as well as
locating alerts on incidental variants (Task 13) had the lowest task
completion rate and error-free rate (14.3% each); however, none of
this information was previously provided to clinicians prior to GIC
and the value of the incidental variant information is debatable,
which will be explained in more detail in Section 4.
Average grades on all tasks, reﬂecting ease of the task, ranged
from B to A. Grades were assigned by each participant at the com-
pletion of each task. The moderator asked the participant to assign
a grade based on how easy/difﬁcult the task was to accomplish.
The highest average grade was given to the task of locating the evi-
dence for a variant update, which was information of high value to
the users. The two tasks that received the lowest grades included
locating patients with the same variant after reviewing the variant
in a single initial patient (Task 11) and reviewing the GIC alert
summary email (Task 14).
Based on completion rate and error-free rate, Tasks 6, 8, 9 and
13 showed the greatest room for improvement. Task 8 required
the user to mark a variant reviewed by locating and using the but-
ton on the Individual Reported Variant Interpretation History page
(Fig. 2). Task 9 involved locating information on all of a patient’s
variants, including updates that had already been reviewed.4. Discussion
We assessed the usability of a tool for helping clinicians follow-
ing patients who have had genetic testing. The clinicians identiﬁed
a number of opportunities to improve the tool which were rela-
tively straightforward to implement, including the addition of
ordering provider to variant and report alerts and clariﬁcation of
some language and labeling. Other modiﬁcations, such as the revi-
sions to the icon scheme, took more development effort. Partici-
pants were enthusiastic about the possibility of receiving updates
on variant information proactively, reducing their need to call
the lab a day before a patient visit to quickly seek this information.
One participant stated ‘‘this tool is important for any disease man-
agement where genotype comes into play. If we do not integrate
this information with patient care we will never learn how and
when to integrate genetic information into medicine’’.
We learned that an interface that makes it very clear to the cli-
nician what new knowledge is available and the potential signiﬁ-
cance of that information for patient and family treatment is
important in displaying genetic data. Our ﬁndings suggest that cli-
nicians, when reviewing genetic knowledge, like to have the evi-
dence that supports a change in a variant’s signiﬁcance and a
clear understanding of exactly what has changed. It provides them
with more conﬁdence in making appropriate decisions for the pa-
tients and family. The usability ﬁndings help illuminate issues that
may hinder the clinician from locating the relevant information as
efﬁciently and effectively as possible. The lessons learned during
the usability tests informed enhancements to the application that
support a user’s optimal use of the tool and will continue to inform
future development.As a result of the usability testing, the development team made
several modiﬁcations to the application. The current release in-
cludes changes to the clinic emails and the interface that now
specify the ordering provider. In the initial release authorized
clinic users received alerts for all of the patients within their clinic,
with no indication of which provider ordered each test. This was
problematic for the busy clinicians who want to know immedi-
ately whether they need to be worrying about a variant update
or particular test result on one of their patients. In the current re-
lease, the ordering providers are displayed for each case. In a fu-
ture release, clinicians will be able to elect to receive alerts only
for reports which list them as an ordering provider, as opposed
to alerts for all providers in a clinic. In addition, the summary
email was reorganized with high alerts at the top of the email. Par-
ticipants felt that the high variant update alerts were the most
important items and should appear ﬁrst in the summary email.
Also, the new report alerts in the summary emails were revised
and are now labeled as medium rather than high level alerts,
which allow the user to easily distinguish the variant updates of
high importance.
To assist GIC users in locating those patients that have impor-
tant information to be reviewed, icons were used in the search re-
sults and on the Tests page. In the initial version of GIC,
inconsistencies in the behavior and application of some of the
icons with external conventions and among screens of the applica-
tion led participants to misunderstand the process or status of the
data presented. Our ﬁndings suggested that the initial design
tested with users did not provide the participants with a clear indi-
cation on the search page of whether a variant update existed and/
or whether it had been reviewed by someone at the clinic. In
designing applications that introduce a newworkﬂow or new func-
tionality, careful consideration should be taken to understand the
current process it will be supporting and how the design could
alleviate some of the mental effort required of the clinician, allow-
ing the clinician to focus on the information important for treating
their patients. In an environment where more than one person
could potentially review one variant update, using the system to
aid the clinician in recognizing those updates easily from the
search results is important. As a result of this study, modiﬁcations
were made to the icons used throughout the application in their
design, placement and behavior. They were revised to more accu-
rately and consistently reﬂect their meaning.
Additional modiﬁcations made to the application include small
changes to the labels on the review buttons, and the counts of
cases and families reported with a variant. Some language used
in the application, such as the ‘‘reported and families counts’’,
was a point of confusion for some of the participants. This could
be due, in part, to the fact that GIC was presenting this information
in a more structured way than it was presented in written labora-
tory reports from the lab prior to the application. Clinicians were
familiar with ﬁnding that type of information in the evidence for
the change in variant category where additional context was pro-
vided. Participants during the usability test were not looking for
a structured ﬁeld for this and when asked about the counts they
were not always sure whether the numbers reﬂected the lab
counts or counts found in the literature or both. The ﬁndings from
the usability tests indicate that providing the right amount of de-
tailed information and choosing the appropriate language is
important, and could possibly reduce errors of interpretation. In
this case, additional user research early in the development cycle
may have been helpful. Providing this variant information in this
format is new to the providers and therefore using familiar and
clear language could help ease the transition and integrate the sys-
tem into the providers’ current model. To achieve this, a label
change was made to clarify that the reported and families count
refers to those identiﬁed by the lab only.
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but critical. Organizing and navigating this patient information so
it can easily be interpreted by the clinician and shared with the pa-
tient will get more complex as the volume of testing increases and
the number of variants per test increases. In this context it is
important to identify and address aspects of the interface that
can be distracting and not critical in supporting the user in accom-
plishing their main goal. In the version tested with users, incidental
variants, which are not often reported by labs, are hidden by de-
fault on the Tests page and the user must click a link to reveal
the incidental variant and any associated updates. Alerts can be
associated with the incidental variants, but ﬁnding these alerts re-
quires ‘‘un-hiding’’ the incidental variants. Some participants had
trouble locating this information even though they were aware
an update was available as indicated by the icon on the search
page. The GIC was originally designed this way with the intention
of reducing the risk that a clinician will misinterpret their signiﬁ-
cance. Especially since incidental variants are not clinically critical
to convey, ﬁnding the balance between providing the clinician with
all information versus limiting information to only that which is
most clinically relevant is challenging. These ﬁndings have initi-
ated a discussion within the GeneInsight team as to whether this
functionality (low level alerts on incidental variants) should be re-
moved from the application. As the volume of test results and var-
iant updates increases over time, the time clinicians are able to
spend reviewing variants and reports will decrease. Identifying
and addressing any distracting elements of the interface may assist
the clinicians in accomplishing the more critical tasks.
The subjective grade given by participants after each task sug-
gests that their perception of the application is different than its
actual performance in some cases. In instances such as this, the va-
lue of the tool in many ways may inﬂuence the clinician’s subjec-
tive assessment of its usability. People may be more willing to
accept small problems when the beneﬁt of the application is much
greater than the time and effort required to use it and the cost of
not using the tool is high [31,32]. Also, as a result of the interface
design, in some cases the user is unaware that they have obtained
incorrect information or misinterpreted something. For this reason,
taking the time to conduct usability tests and observe users can
highlight some issues that may not have been articulated by users
otherwise. This, in turn, allows designers and developers to under-
stand underlying problems that users might encounter with the
application to help prioritize their development and enhancement
efforts [11]. A number of issues encountered during the usability
test prompted additional discussions among the design team and
also brought to light broader considerations that would be helpful
to address to optimize its functionality and usefulness for person-
alized medicine. The larger study includes surveys and interviews
with the users to discuss more in depth the utility of the applica-
tion and its use in practice.
In addition to user requirements identiﬁed in the usability tests,
business and regulatory requirements, especially for this type of
application, must be considered during development and imple-
mentation as well. Concerns related to patient privacy and conﬁ-
dentiality, and technology requirements limit the extent to
which certain designs and functionality is possible. It may not al-
ways be possible to respond to user requests as a result of these
requirements. Therefore, it is challenging but essential for the
development team to be aware of and manage these other ele-
ments as well, in order to successfully reach the goals for the Gene-
Insight Suite.
While usability testing is critical, combining it with other user
research methods to understand additional facets of the user expe-
rience with the application is just as important. To understand the
full picture of the utility, usefulness, and integration into clinical
practice, conducting user research early and involving the user ateach stage of the process is important for any new clinical applica-
tion representing complex knowledge.
While the number of participants in this usability study was
small, we studied a large proportion of the current users, and the
usability issues identiﬁed provided signiﬁcant insight into the
user’s interactions with the GIC interface and most likely represent
the majority of total issues [33]. Formative usability testing is use-
ful to conduct on lower ﬁdelity prototypes and changes incorpo-
rated before implementation of applications to save development
and testing time and effort. The development team made many
modiﬁcations as a result of the version one usability tests and
the research team recently completed additional usability tests
on the current version. As personalized medicine evolves, the ideal
tool may require additional research and enhancements to support
the needs of the clinicians.
5. Conclusions
Participants in usability studies encountered a number of
usability issues with the ﬁrst version of this novel application.
However, they were impressed with the potential value of the tool
in forwarding signiﬁcant genetic variant updates immediately and
electronically to the clinicians. In order to ensure effective use of
the application, many of the issues identiﬁed during usability test-
ing sessions were addressed in the most recent version of the soft-
ware. This analysis will also inform future development as well.
Usability evaluations are invaluable to the success of technology
in an emerging area, especially in a complex domain such as genet-
ics. With the potential volume and scope of personalized medicine,
in addition to the burden already placed on clinicians to document
and manage their patients’ information, designing tools that can
alleviate mental load and automate an increasingly challenging
process becomes more critical.
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